Last $27.83 USD
Change Today +0.16 / 0.58%
Volume 7.5K
EPZM On Other Exchanges
As of 10:00 AM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

epizyme inc (EPZM) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/1/13 - $42.71
52 Week Low
11/14/13 - $18.10
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for EPIZYME INC (EPZM)

epizyme inc (EPZM) Related Businessweek News

No Related Businessweek News Found

epizyme inc (EPZM) Details

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops personalized therapeutics for patients with genetically defined cancers. It identifies the genetic alterations that create cancer causing genes, known as oncogenes; selects patients in whom the identified genetic alteration is found; and designs small molecule therapeutic product candidates to inhibit the oncogene. The company has two histone methyltransferases (HMT) inhibitors in clinical development for the treatment of patients with genetically defined cancers. It is conducting a Phase I clinical trial of its product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemias with genetic alterations of the MLL gene; and a Phase I/II clinical trial of another product candidate, EPZ-6438, an inhibitor targeting the EZH2 HMT for the treatment of a genetically defined subtype of non-Hodgkin lymphoma and solid tumors, including INI1-deficient tumors, such as synovial sarcoma and malignant rhabdoid tumors. The company has therapeutic collaborations with Celgene Corporation and Celgene International Sàrl; Eisai Co., Ltd.; and Glaxo Group Limited., as well as companion diagnostic collaborations with Roche Molecular Systems, Inc. and Abbott Molecular Inc. Epizyme, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

74 Employees
Last Reported Date: 02/28/14
Founded in 2007

epizyme inc (EPZM) Top Compensated Officers

Chief Executive Officer, Secretary and Direct...
Total Annual Compensation: $564.7K
President, Chief Financial Officer, Principal...
Total Annual Compensation: $513.2K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $487.5K
Chief Medical Officer
Total Annual Compensation: $463.5K
Compensation as of Fiscal Year 2013.

epizyme inc (EPZM) Key Developments

Epizyme, Inc. Appoints Peter Ho as Chief Development Officer and Michael Shih as Vice President, Business Development

Epizyme, Inc. announced the appointments of Peter Ho, M.D., Ph.D., as Chief Development Officer and Michael Shih, J.D. as Vice President, Business Development. Dr. Ho will lead the company's clinical development, regulatory and translational medicine functions. His prior experience includes positions at Johnson & Johnson, GlaxoSmithKline, DuPont Pharma and Novartis. Mr. Shih will lead the company's partnership strategy and execution. Most recently, he served as senior director of business development at Forest Laboratories.

Epizyme, Inc. Presents at JMP Securities Boston Biotechnology Day, Sep-05-2014

Epizyme, Inc. Presents at JMP Securities Boston Biotechnology Day, Sep-05-2014 . Venue: The Langham Hotel, Boston, Massachusetts, United States.

Jason Rhodes Resigns as President and Chief Financial Officer of Epizyme, Inc., Effective September 30, 2014

Epizyme, Inc. announced that Jason Rhodes, President and Chief Financial Officer, has resigned from the company, effective September 30, 2014. Mr. Rhodes, who has served on Epizyme's leadership team since 2010, will be joining a venture capital firm. The company has a search underway to identify a new chief financial officer, and Mr. Rhodes has agreed to assist Epizyme in an advisory capacity through the end of 2014 to ensure a smooth transition.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EPZM:US $27.83 USD +0.16

EPZM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for EPZM.
View Industry Companies

Industry Analysis


Industry Average

Valuation EPZM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.6x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIZYME INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at